# A Research Study Looking Into the Effect of Semaglutide and NNC0480 0389 on Blood Levels of a Birth Control Pill in Woman After Menopause

> **NCT05153564** · PHASE1 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 27 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Semaglutide 1.34 mg/mL
- **DRUG:** Semaglutide 3.0 mg/mL
- **DRUG:** NNC0480-0389 10 mg/mL
- **DRUG:** NNC0480-0389 30 mg/mL
- **DRUG:** Microgynon®

## Key facts

- **NCT ID:** NCT05153564
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-12-13
- **Primary completion:** 2022-08-13
- **Final completion:** 2022-09-01
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2023-11-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05153564

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05153564, "A Research Study Looking Into the Effect of Semaglutide and NNC0480 0389 on Blood Levels of a Birth Control Pill in Woman After Menopause". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05153564. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*